Overview of the cancer vaccine field: Are we moving forward?

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 8, 2012, Pages 1135-1140

  Kudrin, Alex ^a   Hanna, Michael G ^b  

^a Department of Pharmaceutical Medicine ^*  (United Kingdom)

^b Vaccinogen Inc   (United States)

Author keywords

China; Medical need; Mortality; Pipeline; South Korea

Indexed keywords

ABIRATERONE; CANCER VACCINE; CETUXIMAB; CRIZOTINIB; CYTOTOXIC AGENT; IPILIMUMAB; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SIPULEUCEL T; TRASTUZUMAB; VEMURAFENIB;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; COLORECTAL CANCER; COLORECTAL TUMOR; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEALTH CARE NEED; HEALTH PROGRAM; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NOTE; OVARY TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS TUMOR; PROSTATE CANCER; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; STOMACH CARCINOMA; THYROID TUMOR; TREATMENT INDICATION;

EID: 84866131761     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20474     Document Type: Note

References (13)

1. American Cancer Society. Cancer Facts and Figures, 2011. Atlanta, American Cancer Society, 2011: 1-10.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277- 300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/ caac.20121.
4. World Health Organization. Cancer mortality database, 2010; Available from: http://www.dep.iarc.fr/ WHOdb/WHOdb.htm Accessed April 13, 2012.
5. Insight P. Therapeutic Cancer Vaccines. Datamonitor, 2009: 1-50.
6. Ernst & Young. Beyond borders: Global biotechnology report, 2011: 1-25. Available from http://www.ey.com/GL/en/Industries/Life-Sciences/ Beyondborders-global-biotechnology-report-2012
7. Shirvill J. Innovations and Opportunities in Therapeutic Vaccines. Business Insights, 2010: 1-100.
8. Oxford Biomedica. Oxford Biomedica press release (April 29, 2009) Oxford Biomedica Regains Rights to its Trovax Cancer Vaccine, 2009; Available from: http://www.oxfordbiomedica.co.uk/page.asp?pageid =59&newsid=72 Accessed on April 13, 2012.
9. Fiercebiotech. Cell Genesys and Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer, 2008; Available from: http://www.fiercebiotech.com/press-releases/ cell-genesys- and-takeda-announce-termination-collaboration- agreement-gvax-mmunothera Accessed on April 13, 2012.
10. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-13; PMID:17932254; http://dx.doi. org/10.1126/science.1145720.
11. Gerlinger MR, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-92; PMID:22397650; http://dx.doi.org/10. 1056/NEJMoa1113205.
12. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-96; PMID:21383288; http://dx.doi.org/10. 1200/JCO.2010.33.2312.
13. PharmaLive. Oncology Market Soars in China. PharmaLive. 2011; Available from: http://pharmalive.com/magazines/medad/view. cfm?articleID=9544 Accessed April 13, 2012.